The development of IL-2 conjugated liposomes for therapeutic purposes  by Konigsberg, P.J et al.
 .Biochimica et Biophysica Acta 1370 1998 243–251
The development of IL-2 conjugated liposomes for therapeutic purposes
P.J. Konigsberg ), R. Godtel 1, T. Kissel 2, L.L. Richer 3
Nexstar Pharmaceuticals, San Dimas, CA 91733, USA
Received 20 May 1997; accepted 5 November 1997
Abstract
A unique immunoliposome has been developed as a drug delivery vehicle for immunotherapy. Human recombinant
 .  .interleukin-2 IL-2 has been chemically coupled to the external surface of small unilamellar vesicles SUVs containing
methotrexate as a candidate immunosuppresive agent in order to specifically direct the drug-bearing liposome to activated
T-cells expressing the high affinity IL-2 receptor. This drug delivery system is designed to deliver an immunosuppressive
agent to those cells that actively participate in disorders such as graft rejection without delivering an effective but potentially
toxic drug to all cells of the immune system as well as other healthy tissues. IL-2 was chemically modified with
w x .succinimidyl 4- p-maleidophenyl butyrate SMPB while the receptor binding domain on IL-2 was protected by monoclonal
anti-IL-2 bound to Protein A-Silica Gel. The antibody recognizes the receptor binding domain of the IL-2 molecule. The
 .IL-2 was derivatized with S-succinimidyl-S-thioacetate SATA in order to add an acetyl thioester group to the lipid and
 .create the complex. The derivatized lipid SATA-PE was then part of the liposome formulation containing DSPC:cholesterol:
SATA-PE at a mole ratio of 1.5:1.0:0.26. SMPB-IL-2 was covalently coupled to the external surface of the SUV after
deacetylation of the thioester moiety at pH 7.4 in PBS. Liposomes prepared by sonication or extrusion had an average
diameter of 46–50 nm. SUV-IL-2 bound to the high affinity IL-2 receptor as measured by competitive binding assays and
Scatchard analysis using 111InCl -loaded liposomes The preparation exhibited a binding constant of 30 pM, consistent with2
values for free IL-2 cited in the literature. SUV IL-2 could be used as the sole source of IL-2 for the murine CTLL-2 T-cell
line or for human mitogen-activated PBLs. The presence of IL-2 coupled to the surface was absolutely required for delivery
of the drug to the cell. When methotrexate was encapsulated within the internal aqueous space, receptor-mediated
endocytosis led to the inhibition of proliferation due to delivery of MTX to the cytoplasm of the cell. More than 90% of the
methotrexate was retained within the liposome during storage over a 24-h period at 48C. This immunoliposome represents a
new class of cell specific immunoliposomes whose entry into the cell is controlled by a cell surface receptor. q 1998
Elsevier Science B.V.
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1. Introduction
A novel immunoliposome has been developed as a
vehicle to treat immunological disorders such as graft
rejection which are characterized by abnormally high
 q.levels of cytolytic T-cell CD8 activity. As an
example a 10% increase in IL-2 receptors has been
found on lymphocytes infiltrating renal allografts af-
w xter transplantation in cynomolgus monkeys 1 . At
present there is no therapeutic mechanism available
to direct the delivery of an immunosuppressive agent
to this specific T-cell subset involved in the tissue
rejection process while bypassing healthy tissues and
other cells that do not have an immunological role.
The utility of this complex is further demonstrated by
using it as a tool to study receptor-mediated endocy-
tosis.
 .Liposomal IL-2 SUV-IL-2 is a small unilamellar
 .vesicle SUV with human recombinant IL-2 cova-
lently coupled to the external surface and an
immunosuppressive agent designed to suppress
metabolic and cytolytic activity of CD8q cells encap-
sulated within the internal aqueous space. We have
taken advantage of the presence of high affinity IL-2
receptors on activated CD8q cells as a tool to attract
IL-2 bearing liposomes to them and thus control the
desired cell specificity of immunosuppressive therapy
to clonally expanded T-cells while minimizing drug
delivery to healthy tissue. Immunotoxins using an
antibody to either the IL-2 or T-cell receptor have
wbeen studied as cell specific immunotherapeutics 2–
x5 .
Antigen-stimulated T-cells express the high affin-
 . w xity interleukin IL-2 receptor on their cell surface 6 .
This lymphokine is absolutely required for CD8 T-cell
w xdevelopment 6 and is produced by T-helper cells
 q.CD4 cells. The high affinity IL-2 receptor is a
 . trimer, composed of the a 55,000 kDa ,b 75,000
.  . w xkDa and g 60,000 kDa subunits 2,7,8 . The b
subunit can independently bind IL-2 and is responsi-
ble for signal transduction and proliferation events.
The association constant of the high affinity receptor
for IL-2 is 10y12 M. Non-activated cells fail to
express the high affinity IL-2 receptor. High affinity
IL-2 receptor have been on B cells and monocytes
w x6 .
The aim of this study was to prepare an immunoli-
posome with human recombinant IL-2 covalently
coupled to the external surface that would be recog-
nized by the IL-2 receptor. The distinguishing feature
of this drug delivery vehicle is that the covalently
coupled IL-2 would remain bioactive and retain both
its receptor binding and growth factor activities in
addition to as serving as the directing agent of the
w xcomplex 2–4,9 . Antiproliferative activity would then
be due to the intracytoplasmic delivery of the encap-
sulated immunosuppressive agent. More importantly,
spurious delivery of the drug to cells that do not
express the IL-2 receptor would not occur.
In contrast, IL-2 fusion toxins which are hybrid
molecules made up of receptor specific ligands or
antibodies and a portion of highly toxic plant or
bacterial toxins can only deliver one molecule of
fusion toxin per receptor rather than many more
molecules of drug encapsulated within the liposome.
Here we present a description of the preparation and
 .properties of liposomal IL-2 SUV IL-2 .
2. Materials and methods
2.1. Phospholipids and antibodies
Phosphatidylcholine and distearoyl phos-
phatidyethanolamine were purchased from Avanti Po-
lar Lipids. Protein A silica gel was purchased from
Chromato Chem, Missoula, MT. SMPB Succinimi-
w x.dyl 4- p-maleidophenyl butyrate and the BCA Pro-
tein assay reagent were from Pierce Chemicals.
 .  .Cholesterol 99%q pure and methotrexate MTX
were from Sigma Chemical. SATA S-succinimidyl-
.S-thioacetate was from Cal Biochem. Human recom-
binant IL-2 was from Sandoz, Basel. Alkaline phos-
phatase substrate, AP-coupled goat, anti-rabbit IgG
and triethanolamine buffer were from BioRad. 6-
carboxyfluorescein was purchased from Kodak. Mon-
oclonal and polyclonal anti-human IL-2 were pur-
chased from Genzyme.
2.2. Cell lines and culture conditions
The murine T-cell line CTLL-2 was obtained from
Sandoz, and grown in the presence of human recom-
binant IL-2 at 25 ngrml. Human peripheral blood
 .lymphocytes PBL were isolated from whole blood
using Ficoll–Hypaque, and stimulated for 72 h with 5
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mgrml phytohemagglutinin M, Sigma Chemicals.
All cultures were maintained in ISCOVE’s modified
DMEM, supplemented with 10% fetal calf serum and
antibiotics.
2.3. Proliferation and cytotoxicity assays
The response of PBLs or CTLL-2 cells used as
IL-2 receptor positive cells to liposomal IL-2 with or
without MTX, was assessed after 72 h in culture.
Data presented are the average of two replicates per
concentration assayed. Concentration ranges of free
or encapsulated drug maximally effective were first
established prior to expanding the range. A rigorous
statistical analysis cannot be done. Liposome prepara-
tions were dialysed at 48C against serum-free media,
sterile filtered by passage through 0.22 mm filters,
and serially diluted in the wells of 96-well culture
plates. Aliquots of cells were then added with antibi-
otics to a density of 2=104 cellsrwell. Cultures
were incubated for a total of 16 h. Prior to termina-
3 .  .tion of the assay, H TdR 0.5 mCirwell was added
and cells incubated for an additional 5 h. The cells
were harvested onto glass fiber filters with a cell
 .harvester Skatron and counted with Bioflour, New
England Nuclear.
2.4. Preparation of monoclonal anti-IL-2 resin
400 ml of Protein A Silica Gel in a siliconized
glass column was washed successively at 228C with
10 ml Dulbecco’s Caqq–Mgqq free PBS, pH 8.6,
PBS q1.0 M NaCl, 0.2 M Na citrate, pH 3.5, and
finally PBS until no protein was detectable in the
washes. 1–2 mg of monoclonal anti-IL-2 in PBS was
added to the resin and allowed to bind for 30 min.
The resin-bound antibody was washed with PBS until
all non-bound antibody was removed as monitored by
the BCA protein assay. The resin was then washed
with PBS containing 12.5% gluteraldehyde, pH 7.4
and finally with PBS. All operations were carried out
at room temperature.
2.5. Modification of IL-2 with SMPB on Anti-IL-2
resin
Modification of IL-2 to prepare SMPB-IL-2 was
carried out on the antibody affinity resin in order to
protect the IL-2 receptor binding domain of the pro-
tein. IL-2 at 2 mgrml was dissolved in 0.05% acetic
acid. 100–200 mgrml was then added to the column
in PBS, pH 7.4 and incubated 16 h at 48C.
The resin was washed extensively with buffer to
remove non-bound IL-2 The amount of non-bound
protein was quantitated by the BCA assay and thus
the amount of resin-bound IL-2 determined. SMPB in
dioxane was then added to give a five-fold molar
excess of reagentrIL-2 and modification carried out
for 10 min at 228C. The reaction was quenched by
the addition of 10 mM Tris buffer, pH 8.0. The
modified IL-2 was eluted from the resin with 0.05 M
Tris, pH 8.0, 2 M K SCN. SMPB IL-2 was stored in
the presence of 0.1% BSA, 0.2 mM PMSF at 48C.
2.6. Preparation of SATA-modified phos -
phatidylethanolamine
Use of SATA introduces a protected thiol group
w xinto proteins 10 . In the course of this study, it was
found that this reagent successfully adds a sulfhydryl
to the prim ary am ino group of phos -
phatidylethanolamine as well. The modified phospho-
lipid is called SATA-PE. A five-fold molar excess of
 .SATA was added to DSPE in CHCl :MeOH 7:33
 .containing triethanolamine 1r250 volume . Modifi-
cation was allowed to proceed for 2 h, 228C under
nitrogen. A three-fold volume excess of acetonitrile
was added and the material stored at y208C for 1–2
h. The precipitate containing SATA-PE was collected
by filtration and then redissolved by washing with
CHCl . The SATA-PE was purified on preparative3
 .TLC in CHCl :MeOH 7:3 with a yield of )80%.3
The R of SATA-PE was 0.68. The modified phos-f
pholipid was stable for over 12 months when stored
 .under nitrogen at y208C in CHCl :MeOH 2:1 .3
2.7. Preparation of small unilamellar ˝esicles
 .Small unilamellar vesicles SUVs were prepared
from DSPC:cholesterol:SATA-PE with a mole ratio
of 1.5:1.0:0.26 by hydrating a dried lipid film with
PBS, pH 7.4 at 658C for 60 min. The lipid suspension
was sonicated for 10 min at 658C with a probe
sonicator and then annealed for 10 min at the same
temperature. Particles of titanium were removed by
centrifugation; 12,000=g for 10 min. Attempts were
also made to prepare immunoliposomes by extrusion
where the resulting diameter of the SUVs was 90 nm.
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Use of this approach was abandoned due to the lack
of consistency in the handling of the extruder
 .Avanti . All data are presented using sonicated
SUVs.
2.8. Size determination of immunoliposomes
Sizing data were collected on a NICOMP model
.270 at 258C.
The date were collected in a volumerweight mode
and expressed using a Gaussian distribution.
2.9. Encapsulation of methotrexate or 6-carboxyfluo-
rescein
Methotrexate in PBS, pH 7.4, was added to the
hydrated lipid film prior to sonication. The lipid
micelles and drug were sonicated together and non-
encapsulated drug was removed by chromatography
3 .on Sephadex G 50–80 in PBS. H Methotrexate was
added to quantitate the degree of encapsulation and to
monitor any drug leakage. Leakage was followed by
incubating SUV-MTX at 48C or 378C for 72 h in
sterile buffer or serum-containing media. Aliquots
 .were centrifuged 2–3000=g for 10 min in Cen-
 .trifree filter units Amicon . Aliquots of the filtrate
were counted in Bioflour. Liposomes containing 6-CF
were also prepared by co-sonication and chromato-
graphed as described. Starting concentrations of MTX
or 6-CF were 200 mgrml and an encapsulation
efficiency of approximately 5% was achieved.
2.10. Co˝alent attachment of SMPB-IL-2 to SATA-PE
SUVs
All steps in the following reaction sequence were
carried out under nitrogen. Pre-formed SATA-PE
SUVs were deacetylated by the addition of freshly
prepared 0.5 M hydroxylamine in HEPES buffer pH
.8.0 and agitated for 30 min, 228C. SMPB-IL-2 was
added and crosslinking allowed to proceed for 2 h.
N-ethylmaleimide was added to a final concentration
of 20 mM to block any unreacted sulfhydryl groups
on the liposome surface. We had empirically found
by us that in order to remove any unconjugated IL-2
the pH was raised to 9.2 and SUV-IL-2 was recov-
ered by passage over CM-Sepharose in 0.01 M Tris
buffer, pH 9.2.
2.11. Quantitation of modified IL-2
 .A sandwich ELISA Genzyme was used to quanti-
tate the amount of IL-2 as SMPB-IL-2 or SUV-IL-2
using human recombinant IL-2 as a standard. The
presence of lipid did not interfere with the assay. It
was observed that once IL-2 was coupled to SMPB,
conventional colorimetric assays to determine protein
concentration could not be used due to interference
by SMPB.
2.12. IL-2 receptor binding assays
The murine T-cell line HT-2 was used as an IL-2
receptor expressing cell. Cells were resuspended at
7 125 .10 cellsrml on 0.4 ml Eppendorf tubes. I IL-2
 .NEN, 2–50 mCirmg at 0.1, 1.0 and 10 ngrml was
added as the competing ligand along with dilutions of
SMPB-IL-2, SUV-SMPB-IL-2, or unmodified IL-2
 .25 ngrml . Samples were incubated and then lay-
 .ered onto Silicon Oil SF 1250 , centrifuged at
12,000=g, 10 min and frozen in a dry ice bath. The
tubes were cut to separate cell pellets from super-
natants. Pellets and supernatants were counted in a
 .gamma counter Beckman . The ‘% bound’ was cal-
wculated from cpm pelletsrcpm pelletqcpm super-
x 111natant =100. Liposomes with encapsulated InCl3
were used to identify classes of high, intermediate
and low affinity IL-2 receptors according to Duncan
w x w xet al. 11 and Robb et al. 7 using human mitogen-
stimulated PBL as IL-2 receptor positive cells.
3. Results
3.1. Chemical modification of interleukin-2 and at-
tachment to liposomes
Fig. 1 illustrates a scheme that produces a lipo-
some with IL-2 covalently attached to its external
surface. In order to retain biological activity of the
targeting molecule to achieve successful drug deliv-
ery, chemical modification of human recombinant
IL-2 was designed to add linker groups to lysine
residues on IL-2 that were not located within the
domain of the protein. This would not interfere with
the recognition of and binding to the high affinity
w xIL-2 receptor 7,8,12 . In addition, the cross-linking
( )P.J. Konigsberg et al.rBiochimica et Biophysica Acta 1370 1998 243–251 247
Fig. 1. The structure of liposomal IL-2 is represented along with
the scheme for the preparation and covalent attachment of
SMPB-modified human recombinant IL-2 to the external surface
of SUVs. IL-2 represented by the triangle and parallelogram, is
covalently attached to the primary amino group of phos-
phatidylethanolamine. SATA-modified PE was stored at y208C
in CHCl :MeOH and SMPB-IL-2 is stored in PBS, pH 7.4 until3
used in the reactions described.
reaction scheme was specifically chosen to avoid
inactivating the protein by disruption of the disulfide
w xgroup at residues 58–105 on the IL-2 molecule 13 .
Consequently, sulfhydryl-specific reagents were not
used. The amino-specific reagent SMPB was chosen
to react with the lysine residues of the protein at pH
7.4.
This reagent contains a maleimide which is avail-
able for coupling with the sulfhydryl that is exposed
after deacetylation of SATA-PE. This restriction of
modification was accomplished by deriving the pro-
tein with SMPB while simultaneously protecting the
binding domain with the use of a monoclonal anti-
body-affinity resin. The resin was composed of silica
gel-protein A and anti-human IL-2 whose epitope
was the receptor binding domain of IL-2. The interac-
tion of IL-2 and antibody served to hide the binding
domain from chemical modification.
The preparation of SATA-PE, a derivatized form
of phosphatidylethanolamine containing a blocked
sulfhydryl group available for coupling after deacety-
lation, has not been previously described in the litera-
ture. SATA has previously been used only as a
modifying and cross-linking reagent for proteins by
w xattaching to the primary amino groups 7,8,12 .
SATA-PE has been found to be extremely stable. It
can be prepared in large enough quantities and stored
in solution at y208C with complete integrity of the
thioester moiety. The resin was stable for 6–8 months
if stored in the presence of 0.2 mM PMSF AT 48C.
Liposomes containing SATA-PE were deacety-
lated to generate a free sulfhydryl which would react
with the maleimide of SMPB addition of N-ethyl-
maleimide was added to block reactive sulfhydryl
groups appearing after deacetylation of SATA-PE on
the liposomal surface which could produce aggre-
gates joined by disulfide bonds.
3.2. Physical characterization of SUV-IL-2
Preparations were characterized in terms of size,
receptor binding activity, stability and the retention of
the encapsulated drug. Sonicated empty liposomes,
SUV-IL-2 or liposomes with encapsulated MTX were
consistently 48–50 nm in diameter. The particle size
of SUV-IL-2, SUV-MTX-IL-2, and SUV-MTX, as
determined by laser light scattering analysis
 .NICOMP , were 46.1, 47.2 and 47.7 nm respec-
tively. The presence of IL-2 bound to the external
surface did not alter the diameter of the vesicle.
3.3. Receptor binding studies
The capacity of SUV-IL-2 or SMPB-IL-2 to bind
the IL-2 receptor on murine T-cells was followed
over a fourteen day period with a series of competi-
125 .tion binding assays in the presence of I IL-2 as
indicated in Fig. 2. Data expressed as ‘% bound’
versus the concentration of the competing form of
IL-2 demonstrate consistent behavior in the ability of
either SMPB-IL-2 or SUV-IL-2 to compete with
125 .I IL-2 for occupancy on the receptors of HT-2
cells. The concentrations of competitors used were at
saturating levels in each study. Liposome-coupled
IL-2 bound with less affinity than SMPB-IL-2 to the
receptor at each concentration and at each time point
examined. Even though the native form of IL-2 was
the most effective competitor for occupancy on the
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Fig. 2. Competitive receptor binding for the IL-2 receptor on
 .murine HT-2 cells using SMPB-IL-2 open triangles , liposomal
 . IL-2 closed triangles and human recombinant IL-2 open cir-
. 125  .cles to displace I-IL-2 closed circles for occupancy on the
receptor. Three concentrations of 125I-IL-2 were used and com-
peting forms of IL-2 were used at 5 mg per samples. Binding
studies were carried out for 14 days during which time sterile
samples of SMPB-IL-2 and SUV-SMPB-IL-2 were stored at 48C.
Data is expressed as ‘% bound’.
receptor, the ability of SUV-IL-2 or the derivatized
but unconjugated SMPB-IL-2 to bind to all classes of
the receptor remained constant during storage when
followed over a fourteen day period.
111 .SUV-IL-2 containing In EDTA was used to
determine the receptor binding constants using mito-
gen-activated human peripheral blood lymphocytes
and the data analyzed by Schatchard analysis. The
111 .binding constants obtained for In SUV-IL-2 were
3.2=10y11M and 2.61=10y10 M. In the same
125 .system, I IL-2 had a binding constant of 2.08=
10y12 M and 3.33=10y10 M. By comparison, Robb
w xet al. 7 obtained receptor binding constants of 3.6=
10y12 M and 2.83=10y11 M. Preliminary data indi-
125 .cated that SUV IL-2 competed with I IL-2 for
binding to the b subunit of the IL-2 receptor visual-
ized by autoradiograms.
3.4. Leakage studies
The phospholipid formulation chosen was suffi-
ciently stable since only a small fraction of encapsu-
lated MTX had leaked out during a 72-h period.
Leakage from SUV-MTX averaged 1% or less at 48C
and 4% at 378C. Leakage from SUV-MTX-IL-2 aver-
aged 2% or less at 48C and 3% at 378C. As expected,
more of the drug leaked out when vesicles were
incubated in serum-containing medium at 378C. Co-
valently coupled IL-2 did not appear to alter the
retention of this drug within the internal aqueous
space of the liposome.
3.5. Growth stimulation by SUV-IL-2
Liposomal-IL-2 supported the growth of PHA-
stimulated PBL in a concentration dependent manner
Fig. 3. The growth response of CTLL-2 cells to SUV-IL-2 as the
IL-2 source was followed by incubation of the cells with SUV-
IL-2 serially diluted in growth medium to generate the concentra-
tion range of coupled IL-2 indicated. Growth was measured by
the incorporation of 0.5 mCirml uridinerwell.
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as shown in Fig. 3. Half maximal stimulation of
growth occurred with 3.9 ngrml IL-2 in the form of
SUV-IL-2. This indicates that the IL-2 on the lipo-
some was recognized by the receptor and internalized
as is the unconjugated IL-2, supporting growth and
proliferation. Further evidence demonstrating the
SUV-IL-2 is internalized is provided by a study
where CTLL-2 cells were incubated with vesicles
 .containing 6-carboxyfluorecein 6-CF . Cells incu-
bated for one hour at 378C exhibit punctate fluores-
cence at the periphery of the cytoplasm as well as
fluorescent material distributed within the cytoplasm
as shown in Fig. 4. This would indicate that SUV-IL-2
had been internalized by the IL-2 receptor and had
been sequestered in lysosomes.
Fig. 4. The internalization of liposomal IL-2 was demonstrated
by observing the presence of encapsulated 6-carboxyfluorescein
after incubation of CTLL-2 cells with liposomes for 30 min at
378C in growth medium. The cells were then cytospun onto glass
slides. The brightfield image is presented along with the fluores-
cent micrograph at 100= magnification.
Fig. 5. The inhibition of CTLL-2 proliferation by SUV-MTX-IL-2
at a constant concentration of IL-2 was monitored by incubation
of cells for 72 h. SUV-MTX-IL-2 was diluted with SUV-IL-2 in
growth medium to a final IL-2 concentration of 25 ngrml.
CTLL-2 at 2=105 cellsrml were incubated with liposomes and
then pulsed for 5 h with 0.5 mCirwell of 3H uridine.
3.6. Growth inhibition of mitogen-stimulated PBLs by
SUV-MTX-IL-2
In order to directly follow the dose-related inhibi-
tion of proliferation by SUV-MTX-IL-2, IL-2 recep-
tor positive cells were incubated with a constant
concentration of IL-2 while varying the concentration
of the drug. This was achieved by using a mixture of
SUV-MTX-IL-2 and SUV-IL-2 where the variable
was MTX. The concentration of liposomal IL-2 gen-
erated in this way was maintained at 25 ngrml. The
data in Fig. 5 present a clear dose-response inhibition
of proliferation due to the presence of MTX, where
the source of the drug was SUV-MTX-IL-2. In addi-
tion, inhibition would not have occurred if the drug
had not been delivered into the cytoplasm by recep-
tor-mediated endocytosis. No inhibition of prolifera-
tion was due to the presence of SUV MTX under the
same conditions. cells if the cells were incubated with
SUV-IL-2 in combination with the free drug. Other
immunoliposomes have been shown to deliver
daunorubricin to the cytoplasm leading to cell death
w x14,15 .
4. Discussion
Liposomes have long been used as a research tool
to study the physical and chemical properties of
biological membranes. Phospholipid vesicles both as
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multilamellar or small unilamellar vesicles are now
being used as drug delivery systems as well as probes
of cell structure and function. Liposomes are
biodegradable, non-toxic, and enable encapsulated
pharmacological agents to exhibit longer circulation
lifetimes in vivo as compared to the non-encapsulated
w xdrug 13 . The limitations of current therapies to treat
graft rejection has led to the development of a lipo-
some-based drug delivery system that would restrict
the uptake of immunosuppressive drugs to only those
cells of the immune system that were actively en-
gaged in graft rejection rather than producing sys-
temic delivery of the drug as is usually the case.
Another aspect of the study is that this form of
targeted liposome can be used to modulate intra-
cellular activity such as DNA synthesis in the ab-
sence of the drug.
Targeting a vesicle to the IL-2 receptor mandates
that a critical concentration of the b subunit is
present to elicit delivery of the drug. This situation
would be found on activated CD8q cells. In addition,
there is a need to develop other modes of drug
therapy since the toxicity of many immunosuppres-
sive agents often compromises their efficacy.
Decreasing drug toxicity is a hallmark of liposome
encapsulated drugs. Liposomal FK506 tested in a
canine liver transplantation model was found in higher
concentrations in the liver and spleen and had de-
w xcreased levels in the kidney 16,17 . Decreased
nephrotoxicity was observed using liposomal cy-
w xclosporine 18 . Liposome-encapsulated methylpred-
nisolone prolonged cardiac allograft survival in rats
w x19 . However, none of these liposomal systems could
be targeted to a specific T-cell subset or any other
group of cells actively involved in the disease process
and can potentially interact with non-involved cells.
Anti-transferrin and anti-TAC liposomes have been
developed as a targeted immunoliposome to treat
w xgraft rejection 20,21 . IL-2 has been incorporated
into multilamellar liposomes as another means of
delivering it with greater circulating life time. This
type of complex has also exhibited bioavailability to
w xsome extent 5 . Our method of covalently coupling
IL-2 to the external surface of liposomes implies that
bound molecules demonstrate bioavailability as seen
in Fig. 3.
The use of IL-2 as a targeting ligand is also being
exploited by the development of immunotoxins.These
are constructed from IL-2 or monoclonal antibodies
linked chemically to toxins or as fusion proteins of
w xIL-2 and bacterial toxins 6,2–4,9–11 . These hybrid
molecules have also been prepared as another means
of delivering antiproliferative drugs to cells involved
w xin graft rejection in a cell-specific manner 9,14,22 .
However, these immunotoxins may themselves be
immunogenic. Moreover, the concentration of drug
delivered by immunotoxins is limited by the total
number of toxin-conjugated molecules of IL-2 pre-
sent even though the toxins themselves are quite
potent. A far greater concentration of drug is deliv-
ered using a liposome as a drug carrier rather than a
single toxin molecule.
Confocal microscopy studies demonstrate that the
entry of liposomes is into intracytoplasmic vesicles
w x14 . Liposomes with anti-c-erb-2 conjugated to the
outside and doxorubicin encapsulated internally have
been found to suppress the growth of human breast
w xtumor cells in culture 23 . Efficient internalization of
anti-p185 Her 2 liposomes was observed by light and
electron microscopy and had occurred by receptor-
w xmediated endocytosis 24 .
These data do reflect an in vitro mode of targeted
drug delivery to IL-positive receptor cells. Such cells
in vitro would also be mainly those of T-cell lineage.
Macrophage do phagocytose particulate antigens and
process them for antigen presentation. It remains to
be seen how SUV-MTX-Il-2 would be partitioned, if
at all, between various groups of lymphocytes during
therapy.
Methotrexate was chosen only as a candidate im-
munosuppressive drug because of its chemical prop-
erties. It is often used as an immunosuppressive agent
in the treatment of rheumatoid arthritis, in addition to
w xbeing an antineoplastic agent 15,13,25 . It is water
soluble and would be sequestered within the internal
aqueous space, is easily monitored in radioactive
form, and is largely retained during storage.
SMPB-modified IL-2 is recognized by anti-IL-2
and quantitated by an ELISA is biologically active
 .24 . An interesting feature of this work is that
modified IL-2 is internalized by the receptor and
therefore initiates proliferative events as seen in Fig.
2. This in turn makes them more sensitive to inhibi-
tion by MTX.
In addition, modified IL-2 is stable in solution at
48C and was able to compete for binding to the IL-2
( )P.J. Konigsberg et al.rBiochimica et Biophysica Acta 1370 1998 243–251 251
receptors on HT-2 cells, a murine T-cell line, over a
 .fourteen day period Fig. 2 . Both SATA-PE and
IL-2 are stable and can be stored at 48C prior to
w xcoupling 15,13,25 . The stability of SUV-IL-2 also
makes it a useful reagent for examining receptor-
mediated endocytosis in culture.
The methods described feature IL-2 as a targeting
agent to create cell specificity in a liposome-based
drug delivery system that otherwise lacks any cell or
tissue specificity. Clearly, any cell specific ligand
that has a unique high affinity receptor that is unique
to a particular tissue or appears to be developmen-
tally regulated could be used in this scheme to achieve
the same function as IL-2 does with lymphocytes in
the immune system thereby achieving specific drug
delivery.
These data do reflect an in vitro mode of targeted
drug delivery to IL-positive receptor cells. Such cells
in vitro would also be mainly those of T-cell lineage.
Macrophage do phagocytose particulate antigens and
process them for antigen presentation. It remains to
be seen how SUV-MTX-IL-2 would be partitioned, if
at all, between various groups of lymphocytes during
therapy in vivo.
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